Sethi Manveen K, Fanayan Susan
Department of Chemistry and Biomolecular Sciences, Macquarie University, North Ryde, NSW 2109, Australia.
Department of Biomedical Sciences, Macquarie University, North Ryde, NSW 2109, Australia.
Int J Mol Sci. 2015 Dec 9;16(12):29278-304. doi: 10.3390/ijms161226165.
Colorectal cancer (CRC) is one of the most prevalent cancers worldwide. An increased molecular understanding of the CRC pathology is warranted to gain insights into the underlying molecular and cellular mechanisms of the disease. Altered protein glycosylation patterns are associated with most diseases including malignant transformation. Recent advances in mass spectrometry and bioinformatics have accelerated glycomics research and present a new paradigm for cancer biomarker discovery. Mass spectrometry (MS)-based glycoproteomics and glycomics, therefore, hold considerable promise to improve the discovery of novel biomarkers with utility in disease diagnosis and therapy. This review focuses on the emerging field of glycomics to present a comprehensive review of advances in technologies and their application in studies aimed at discovering novel glycan-based biomarkers. We will also discuss some of the challenges associated with using glycans as biomarkers.
结直肠癌（CRC）是全球最常见的癌症之一。有必要加深对CRC病理学的分子理解，以深入了解该疾病潜在的分子和细胞机制。蛋白质糖基化模式的改变与包括恶性转化在内的大多数疾病相关。质谱和生物信息学的最新进展加速了糖组学研究，并为癌症生物标志物的发现提供了新的范例。因此，基于质谱（MS）的糖蛋白质组学和糖组学在改善新型生物标志物的发现方面具有很大的前景，这些生物标志物可用于疾病诊断和治疗。本综述聚焦于糖组学这一新兴领域，全面回顾技术进展及其在旨在发现新型基于聚糖的生物标志物的研究中的应用。我们还将讨论与使用聚糖作为生物标志物相关的一些挑战。
